Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Otorhinolaryngology-Head and Neck Surgery, Osaka Rosai Hospital, Sakai, Japan.
Anticancer Res. 2021 Apr;41(4):2045-2051. doi: 10.21873/anticanres.14973.
BACKGROUND/AIM: To retrospectively evaluate the efficacy and safety of modified TPEx (docetaxel 60 mg/m on day 1, cisplatin 60 mg/m on day 1, and weekly cetuximab 250 mg/m with loading dose of 400 mg/m) followed by maintenance cetuximab as first-line treatment for inoperable recurrent and/or metastatic squamous cell carcinoma of the head and neck.
We analyzed 22 Japanese patients receiving modified TPEx every 21 days for four cycles with or without prophylactic granulocyte colony-stimulating factor (G-CSF).
The best overall response rate was 55% [95% confidence interval (CI)=35-73]. The median progression-free survival and overall survival were 8.9 months (95%CI=3.9-10.2) and 14.3 months (95%CI=10.1-28.2), respectively. Without prophylactic G-CSF, Grade 3/4 neutropenia and febrile neutropenia was common (94% versus 20%; p=0.003 and 41% versus 0%; p=0.11, respectively).
The modified TPEx is effective, while prophylactic G-CSF is essential.
背景/目的：回顾性评估改良 TPEx（第 1 天给予多西他赛 60mg/m2，顺铂 60mg/m2，每周给予西妥昔单抗 250mg/m2，首剂给予 400mg/m2）联合维持治疗作为不可切除复发性和/或转移性头颈部鳞状细胞癌的一线治疗的疗效和安全性。
我们分析了 22 例日本患者，每 21 天接受改良 TPEx 治疗 4 个周期，有无预防性粒细胞集落刺激因子（G-CSF）治疗。
最佳总体缓解率为 55%[95%置信区间（CI）=35-73]。中位无进展生存期和总生存期分别为 8.9 个月（95%CI=3.9-10.2）和 14.3 个月（95%CI=10.1-28.2）。无预防性 G-CSF 时，常见 3/4 级中性粒细胞减少和发热性中性粒细胞减少（94%比 20%；p=0.003 和 41%比 0%；p=0.11）。
改良 TPEx 有效，而预防性 G-CSF 是必需的。
